17 May 2013 - 17 May 2013 - French Sanofi (EPA:SAN) said today that its Phase III study of the JAK2 inhibitor SAR302503 for myelofibrosis (MF) met its primary endpoint in both dose groups.

The primary endpoint evaluated the proportion of patients achieving >35% reduction of spleen volume. The most common adverse events were anaemia, diarrhoea, nausea and vomiting.

The randomised, double-blind, placebo-controlled Phase III study, dubbed JAKARTA, assessed once-daily oral SAR302503 versus placebo in 289 patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis.

The company said further that it will report full data at an upcoming medical event.